The purpose of this study was to develop a breast cancer model in rats, in which myeloablative chemotherapy and syngeneic bone marrow transplantation (SBMT) could be evaluated systematically for therapeutic effect. The Wistar-Furth (WF) DMBA-4 breast cancer cell line transplanted into naive WF rats produced rapidly growing tumors that were lethal within 2 months. SBMT was performed following preparation with a regimen (Bu-Cy), consisting of busulfan 16 mg/kg by gastric gavage on days À3 and À2 followed by 250 mg/kg of cyclophosphamide i.p on day À1. Marrow was prepared from the femurs of donors and infused i.v. into the recipient on day 0. In all, 15 rats treated with Bu-Cy without marrow died, while 22 of 25 transplanted rats survived. In total, 16 rats with measurable tumors showed tumor responses following transplantation, but tumors recurred and survival was minimally prolonged. Of nine rats transplanted before clinical tumors were detected, five became long-term survivors that resisted further tumor challenge. It was concluded that the DMBA-4 breast cancer in WF rats could serve to evaluate SBMT following myeloablative doses of chemotherapy at various tumor loads. At large tumor loads therapy was not curative, but at low tumor burdens cures were possible and resistance to subsequent tumor challenge was demonstrated. The model may be useful for further studies of stem cell infusion in rodent tumor systems.
Introduction
High-dose chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT) has been used to treat locally advanced and metastatic breast cancer. [1] [2] [3] Following early encouraging reports of positive outcomes, breast cancer became the most common indication for HDC/ABMT. 3 The rationale for its use appeared well-founded, incorporating concepts of dose response, tumor kinetics and stem cell support for hematologic toxicity. [4] [5] [6] In addition, the use of ABMT is well established as an effective therapy for hematologic malignancies. 7, 8 Despite early clinical enthusiasm and widespread application, problems of patient selection, the timing of transplantation and assessment of benefits for patients with breast cancer remain in doubt. 9 Recent controlled trials have failed to demonstrate a clear advantage of ABMT as a component of therapy, 10, 11 although the data are subject to various interpretations. 12, 13 Owing to the major design constraints and time necessary to develop additional clinical trials, we believe it may be useful to examine the high-dose chemotherapy-marrow rescue paradigm in a rodent model system. A seminal series of studies in rats established a high-dose chemotherapy regimen of busulfan and cyclophosphamide (Bu-Cy) appropriate for marrow ablation and evaluation of syngeneic and allogeneic transplantation. [14] [15] [16] This transplant model has not been explored in a breast tumor system in the rat.
Ingestion of 7,12-dimethylbenz(a)anthracene (DMBA) results in the development of breast tumors in rats. The site of origin has been shown to be the terminal mammary ductules. Intermediate dosing (20 mg) of DMBA produces breast tumors that do not metastasize. 17, 18 Tumors with metastatic properties may develop in Wistar-Furth (WF) rats that survive a high dose of DMBA (40 mg) (DMBA-4 cell line). 19 Such tumors are transplantable into naive WF rats and produce local and systemic metastases. 20 The DMBA-4 tumor cell line has been maintained in our laboratory by serial passage. The tumor develops with the morphologic features of high-grade adenocarcinoma which is estrogen and progesterone receptor negative by immunohistochemical staining.
The present studies were directed at developing and assessing the Bu-Cy regimen followed by syngeneic bone marrow transplantation (SBMT) in WF rats challenged with the DMBA-4 breast cancer cell line.
Materials and methods

Rats
Virgin female WF rats weighing between 150 and 200 g, 6-12 weeks of age, were fed normal rat chow and isolated for 1 week prior to use. Following marrow transplantation, housing was carried out in an environmentally controlled laminar air flow unit. Animals were housed in facilities certified by the American Association for the Accreditation of Laboratory Animal Care. The guidelines established in the Guide for the Care and Use of Laboratory Animals (US Department of Health and Human Resources, NIH, 1985) were observed for the studies described in this report and the protocol was approved by the Institutional Animal Care and Use Committee.
Bu-Cy/SBMT treatment
This interventional strategy required a 4-day treatment regimen as follows: on day À3 and day À2, 16 mg/kg of Bu was administered to recipient rats by gastric gavage. On day À1, Cy was administered at a dose of 250 mg/kg body weight by i.p. injection. Marrow for transplantation was obtained by flushing the femoral shafts of euthanized normal donors with heparinized tissue culture media (RPMI Medium 1640, Gibco; Grand Island, NY, USA), containing 10% newborn calf serum. Marrow cell numbers were adjusted by centrifugation to yield 10 7 nucleated cells in a volume of 1.5 ml. On day 0, infusion was carried out by tail vein injection. Rats dying after day 3 and before day 14 were considered to have died during the period of marrow aplasia. This was confirmed by histologic marrow examination in selected rats. Marrow recovery was assumed in rats surviving beyond 14 days.
Tumor challenge
For evaluation of tumor growth and response, rats were challenged with 10 6 DMBA-4 tumor cells as previously described. 20 A cell suspension was prepared from surgically removed progressing tumors, in Dulbecco's modified eagles medium (Sigma; St Louis, MO, USA) containing 7% newborn calf serum and 50 mg/ml gentamycin. The cells were washed, resuspended in 5 ml of media and a volume of 150 ml consisting of 10 6 cells injected into the milk line of naive recipients. All rats were followed until death or euthanized when terminal. Tumor measurements were performed in two dimensions with calipers and volume was calculated by the formula: volume ¼ 4/3pR 1 2 R 2 , where R 1 oR 2 . 21 
Experimental design
Groups of rats consisted of the following: Group 1-14 untreated rats challenged with tumor and followed until death. Group 2-15 rats challenged with tumor received BuCy as described, but did not receive marrow. Group 3-16 rats challenged with tumor received Bu-Cy and SBMT treatment when tumors were between 2.5 and 34 cm 3 . Group 4-9 rats received Bu-Cy and SBMT treatment 7-10 days following tumor challenge, prior to the appearance of clinically measurable tumor masses. Group 5-5 rats rechallenged with tumor 3 months following the induction of a complete response after Bu-Cy and SBMT treatment. Table 1 summarizes the effectiveness of marrow support in rescuing rats from the otherwise lethal dose of Bu-Cy. There were no 14 day survivors in the 15 control nontransplanted rats, while 22 of 25 transplanted rats survived to hematologic recovery. Figures 1a and b illustrate the histology of the marrow in transplanted and nontransplanted rats at comparable days following Bu-Cy administration.
Results
In total, 14 untreated rats challenged with tumor had a median survival of 41.5 days, dying of widespread visceral and nodal metastatic disease. The volumes of index tumors were monitored in six of the rats and are shown in Figure 2a . Tumor growth followed first-order kinetics with a doubling time of approximately 5.5 days. Figure 2b illustrates the tumor volume responses observed in 16 rats treated with Bu-Cy and SBMT at a time when clinically measurable tumors were present. Initial tumor regression responses occurred in all rats, with minimal tumor volumes reached by day 10. In six rats, tumors became nonpalpable. However, all evaluable rats subsequently developed local and metastatic recurrences and died. Of the nine tumor-challenged animals that received BuCy/SBMT treatment before tumors became palpable, one died of marrow toxicity. Table 2 summarizes the data on the eight evaluable rats with nonpalpable tumors that were treated with Bu-Cy/SBMT. Two rats failed to develop tumor when followed for more than 150 days. Five rats developed clinically apparent tumors between 25 and 30 days following tumor challenge, but these tumors ultimately regressed completely by 2 months. Two of the five rats had recurrence of tumor after 100 days and ultimately died of metastatic disease. Figure 2c illustrates the volume changes of primary tumors in these five rats. Five rats, including three rats with complete remission and two rats in which tumor was never detectable, were rechallenged with tumor at approximately 3 months after Bu-Cy/SBMT treatment. None of these rats developed tumors.
The overall survivals of evaluable rats in control and experimental groups are shown in Figure 3 . Animals in which the tumor was not palpable at the time of Bu-Cy/ bone marrow transplantation demonstrated a significantly prolonged survival with five of nine animals surviving tumor-free beyond 150 days. In total, 11 rats transplanted with measurable tumor could be evaluated for survival. Although a tumor regression response was seen in all animals as measured by at least a 50% decrease in tumor volume, subsequent tumor progression occurred. The mean survival in this group was 51.774.0 days, which represents a small but significant (Po0.05) survival advantage compared to untreated, tumor-bearing controls.
Discussion
The present studies confirm that marrow rescue can be regularly achieved in WF rats following an otherwise lethal regimen of Bu and Cy. The DMBA-4 tumor is uniformly responsive to Bu-Cy. However, analogous to findings in man, survival is minimally, if at all, increased when tumor burdens are high. At low tumor burdens, in the absence of clinically measurable disease, survival occurs in some animals. The rationale for the most recent clinical trials has been to evaluate patients in whom tumor burdens are unknown (as following complete responses to chemotherapy) or in an adjuvant setting (patients at high risk following primary therapy). 11, 12 It remains to be seen if a dose-response curve exists for the DMBA-4 tumor that correlates with survival when tumors are advanced. The present study suggests that this is not the case. The model seems appropriate to evaluate regimens limited by marrow toxicity other than Bu-Cy, and to more precisely define tumor mass-response considerations. The tumor model also appears to manifest significant immunologic characteristics. Originally developed in WF rats, it is not transplantable to other inbred strains (unpublished data). In the current studies, rats that failed to develop tumors when treated after tumor challenge but before developing measurable tumor masses were uniformly resistant to tumor growth when tumor cells were transplanted at a later date. These findings indicate that the model may provide for studies of active or passive immunotherapy with either syngeneic or allogeneic cells following chemotherapy-induced responses. Such studies are currently under way.
The highly aggressive nature of this tumor while retaining the histologic characteristics of an estrogen receptor negative tumor derived from breast tissue differs from the more indolent localized estrogen receptor positive tumors that develop after standard doses of DMBA (20 mg/kg) in a variety of strains. 17, 18 Comparative therapeutic efforts in this model may also help to develop a fuller picture of optimal employment of SBMT in rodent breast cancer. SBMT after the presence of palpable tumors (n ¼ 11) and in rats treated with Bu-Cy/SBMT before the presence of palpable tumors (n ¼ 9) compared to untreated controls (n ¼ 14).
